Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy

References

• Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res 2013; 19:1044 - 53; http://dx.doi.org/10.1158/1078-0432.CCR-12-2065; PMID: 23460535
   PubMed Web of Science ®Google Scholar
• Moran AE, Kovacsovics-Bankowski M, Weinberg AD. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol 2013; 25:230 - 7; http://dx.doi.org/10.1016/j.coi.2013.01.004; PMID: 23414607
   PubMed Web of Science ®Google Scholar
• Vinay DS, Kwon BS. Immunotherapy of cancer with 4-1BB. Mol Cancer Ther 2012; 11:1062 - 70; http://dx.doi.org/10.1158/1535-7163.MCT-11-0677; PMID: 22532596
   PubMed Web of Science ®Google Scholar
• Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol 2009; 157:9 - 19; http://dx.doi.org/10.1111/j.1365-2249.2009.03912.x; PMID: 19659765
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010; 37:508 - 16; http://dx.doi.org/10.1053/j.seminoncol.2010.09.008; PMID: 21074066
   PubMed Web of Science ®Google Scholar
• Lin GH, Liu Y, Ambagala T, Kwon BS, Ohashi PS, Watts TH. Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice. PLoS One 2010; 5:e11003; http://dx.doi.org/10.1371/journal.pone.0011003; PMID: 20543982
   PubMedGoogle Scholar
• May KF Jr., Chen L, Zheng P, Liu Y. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res 2002; 62:3459 - 65; PMID: 12067989
   PubMed Web of Science ®Google Scholar
• Miller RE, Jones J, Le T, Whitmore J, Boiani N, Gliniak B, Lynch DH. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol 2002; 169:1792 - 800; PMID: 12165501
   PubMed Web of Science ®Google Scholar
• Wang C, Lin GH, McPherson AJ, Watts TH. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev 2009; 229:192 - 215; http://dx.doi.org/10.1111/j.1600-065X.2009.00765.x; PMID: 19426223
   PubMed Web of Science ®Google Scholar
• Sabbagh L, Pulle G, Liu Y, Tsitsikov EN, Watts TH. ERK-dependent Bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of CD8 T cell survival in vivo. J Immunol 2008; 180:8093 - 101; PMID: 18523273
   PubMed Web of Science ®Google Scholar
• Lee HW, Park SJ, Choi BK, Kim HH, Nam KO, Kwon BS. 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 2002; 169:4882 - 8; PMID: 12391199
   PubMed Web of Science ®Google Scholar
• Curran MA, Geiger TL, Montalvo W, Kim M, Reiner SL, Al-Shamkhani A, Sun JC, Allison JP. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J Exp Med 2013; 210:743 - 55; http://dx.doi.org/10.1084/jem.20121190; PMID: 23547098
   PubMed Web of Science ®Google Scholar
• Banerjee A, Gordon SM, Intlekofer AM, Paley MA, Mooney EC, Lindsten T, Wherry EJ, Reiner SL. Cutting edge: The transcription factor eomesodermin enables CD8+ T cells to compete for the memory cell niche. J Immunol 2010; 185:4988 - 92; http://dx.doi.org/10.4049/jimmunol.1002042; PMID: 20935204
   PubMed Web of Science ®Google Scholar
• Intlekofer AM, Banerjee A, Takemoto N, Gordon SM, Dejong CS, Shin H, Hunter CA, Wherry EJ, Lindsten T, Reiner SL. Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin. Science 2008; 321:408 - 11; http://dx.doi.org/10.1126/science.1159806; PMID: 18635804
   PubMed Web of Science ®Google Scholar
• Intlekofer AM, Takemoto N, Kao C, Banerjee A, Schambach F, Northrop JK, Shen H, Wherry EJ, Reiner SL. Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells. J Exp Med 2007; 204:2015 - 21; http://dx.doi.org/10.1084/jem.20070841; PMID: 17698591
   PubMed Web of Science ®Google Scholar
• Paley MA, Kroy DC, Odorizzi PM, Johnnidis JB, Dolfi DV, Barnett BE, Bikoff EK, Robertson EJ, Lauer GM, Reiner SL, et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 2012; 338:1220 - 5; http://dx.doi.org/10.1126/science.1229620; PMID: 23197535
   PubMed Web of Science ®Google Scholar
• Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988; 54:777 - 85; http://dx.doi.org/10.1016/S0092-8674(88)91043-4; PMID: 3261634
   PubMed Web of Science ®Google Scholar
• Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K, Chapoval AI, Strome SE, Pease LR, Chen L. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 2002; 109:651 - 9; http://dx.doi.org/10.1172/JCI0214184; PMID: 11877473
   PubMed Web of Science ®Google Scholar
• Bansal-Pakala P, Halteman BS, Cheng MH, Croft M. Costimulation of CD8 T cell responses by OX40. J Immunol 2004; 172:4821 - 5; PMID: 15067059
   PubMed Web of Science ®Google Scholar
• Tutt AL, O’Brien L, Hussain A, Crowther GR, French RR, Glennie MJ. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol 2002; 168:2720 - 8; PMID: 11884438
   PubMed Web of Science ®Google Scholar
• Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76:17 - 27; http://dx.doi.org/10.1016/0092-8674(94)90169-4; PMID: 8287475
   PubMed Web of Science ®Google Scholar
• Kim JA, Averbook BJ, Chambers K, Rothchild K, Kjaergaard J, Papay R, Shu S. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res 2001; 61:2031 - 7; PMID: 11280763
   PubMed Web of Science ®Google Scholar
• Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 2011; 6:e19499; http://dx.doi.org/10.1371/journal.pone.0019499; PMID: 21559358
   PubMed Web of Science ®Google Scholar
• Qui HZ, Hagymasi AT, Bandyopadhyay S, St Rose MC, Ramanarasimhaiah R, Ménoret A, Mittler RS, Gordon SM, Reiner SL, Vella AT, et al. CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation. J Immunol 2011; 187:3555 - 64; http://dx.doi.org/10.4049/jimmunol.1101244; PMID: 21880986
   PubMed Web of Science ®Google Scholar
• Henson SM, Akbar AN. KLRG1--more than a marker for T cell senescence. Age (Dordr) 2009; 31:285 - 91; http://dx.doi.org/10.1007/s11357-009-9100-9; PMID: 19479342
   PubMed Web of Science ®Google Scholar
• Tessmer MS, Fugere C, Stevenaert F, Naidenko OV, Chong HJ, Leclercq G, Brossay L. KLRG1 binds cadherins and preferentially associates with SHIP-1. Int Immunol 2007; 19:391 - 400; http://dx.doi.org/10.1093/intimm/dxm004; PMID: 17307799
   PubMed Web of Science ®Google Scholar
• Overwijk WW, Restifo NP. B16 as a mouse model for human melanoma. Curr Protoc Immunol 2001; Chapter 20:Unit 20 1.
   Google Scholar
• Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellström KE, Mittler RS, Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997; 3:682 - 5; http://dx.doi.org/10.1038/nm0697-682; PMID: 9176498
   PubMed Web of Science ®Google Scholar
• Snell LM, Lin GH, McPherson AJ, Moraes TJ, Watts TH. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy. Immunol Rev 2011; 244:197 - 217; http://dx.doi.org/10.1111/j.1600-065X.2011.01063.x; PMID: 22017440
   PubMed Web of Science ®Google Scholar
• Lynch DH. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev 2008; 222:277 - 86; http://dx.doi.org/10.1111/j.1600-065X.2008.00621.x; PMID: 18364008
   PubMed Web of Science ®Google Scholar
• Ito F, Li Q, Shreiner AB, Okuyama R, Jure-Kunkel MN, Teitz-Tennenbaum S, Chang AE. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res 2004; 64:8411 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-04-0590; PMID: 15548712
   PubMed Web of Science ®Google Scholar
• Choi BK, Kim YH, Kang WJ, Lee SK, Kim KH, Shin SM, Yokoyama WM, Kim TY, Kwon BS. Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy. Cancer Res 2007; 67:8891 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-07-1056; PMID: 17875731
   PubMed Web of Science ®Google Scholar
• Ko E, Luo W, Peng L, Wang X, Ferrone S. Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity. Cancer Res 2007; 67:7875 - 84; http://dx.doi.org/10.1158/0008-5472.CAN-06-1744; PMID: 17699794
   PubMed Web of Science ®Google Scholar
• Kim YH, Choi BK, Oh HS, Kang WJ, Mittler RS, Kwon BS. Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy. Mol Cancer Ther 2009; 8:469 - 78; http://dx.doi.org/10.1158/1535-7163.MCT-08-0993; PMID: 19190115
   PubMed Web of Science ®Google Scholar
• Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998; 190:167 - 72; http://dx.doi.org/10.1006/cimm.1998.1396; PMID: 9878117
   PubMed Web of Science ®Google Scholar
• Martinet O, Ermekova V, Qiao JQ, Sauter B, Mandeli J, Chen L, Chen SH. Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model. J Natl Cancer Inst 2000; 92:931 - 6; http://dx.doi.org/10.1093/jnci/92.11.931; PMID: 10841829
   PubMed Web of Science ®Google Scholar
• Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, Lin JT, Irish JM, Torchia JA, Kolstad A, Chen L, et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 2009; 114:3431 - 8; http://dx.doi.org/10.1182/blood-2009-05-223958; PMID: 19641184
   PubMed Web of Science ®Google Scholar
• Murillo O, Dubrot J, Palazón A, Arina A, Azpilikueta A, Alfaro C, Solano S, Ochoa MC, Berasain C, Gabari I, et al. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol 2009; 39:2424 - 36; http://dx.doi.org/10.1002/eji.200838958; PMID: 19662633
   PubMed Web of Science ®Google Scholar
• Li Q, Iuchi T, Jure-Kunkel MN, Chang AE. Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer. Int J Biol Sci 2007; 3:455 - 62; http://dx.doi.org/10.7150/ijbs.3.455; PMID: 18071585
   PubMed Web of Science ®Google Scholar
• Zhu Y, Ju S, Chen E, Dai S, Li C, Morel P, Liu L, Zhang X, Lu B. T-bet and eomesodermin are required for T cell-mediated antitumor immune responses. J Immunol 2010; 185:3174 - 83; http://dx.doi.org/10.4049/jimmunol.1000749; PMID: 20713880
   PubMed Web of Science ®Google Scholar
• Hegel JK, Knieke K, Kolar P, Reiner SL, Brunner-Weinzierl MC. CD152 (CTLA-4) regulates effector functions of CD8+ T lymphocytes by repressing Eomesodermin. Eur J Immunol 2009; 39:883 - 93; http://dx.doi.org/10.1002/eji.200838770; PMID: 19224637
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O’Day SJ, Hoos A, Humphrey R, Berman DM, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 2013; 1291:1 - 13; http://dx.doi.org/10.1111/nyas.12180; PMID: 23772560
   PubMed Web of Science ®Google Scholar
• Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013; 13:5; PMID: 23390376
   PubMedGoogle Scholar
• Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013; 19:997 - 1008; http://dx.doi.org/10.1158/1078-0432.CCR-12-2214; PMID: 23460531
   PubMed Web of Science ®Google Scholar
• Vezys V, Penaloza-MacMaster P, Barber DL, Ha SJ, Konieczny B, Freeman GJ, Mittler RS, Ahmed R. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. J Immunol 2011; 187:1634 - 42; http://dx.doi.org/10.4049/jimmunol.1100077; PMID: 21742975
   PubMed Web of Science ®Google Scholar
• Xiao H, Huang B, Yuan Y, Li D, Han LF, Liu Y, Gong W, Wu FH, Zhang GM, Feng ZH. Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin Cancer Res 2007; 13:1823 - 30; http://dx.doi.org/10.1158/1078-0432.CCR-06-2154; PMID: 17325342
   PubMed Web of Science ®Google Scholar
• Kao C, Oestreich KJ, Paley MA, Crawford A, Angelosanto JM, Ali MA, Intlekofer AM, Boss JM, Reiner SL, Weinmann AS, et al. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat Immunol 2011; 12:663 - 71; http://dx.doi.org/10.1038/ni.2046; PMID: 21623380
   PubMed Web of Science ®Google Scholar
• Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, Akpinarli A, Fulton A, Tamada K, Strome SE, Antony PA. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol 2013; 190:4899 - 909; http://dx.doi.org/10.4049/jimmunol.1300271; PMID: 23536636
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Ngiow SF, Sullivan JM, Teng MW, Kuchroo VK, Smyth MJ, Anderson AC. TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology 2013; 2:e23849; http://dx.doi.org/10.4161/onci.23849; PMID: 23734331
   PubMed Web of Science ®Google Scholar
• Goldberg MV, Drake CG. LAG-3 in Cancer Immunotherapy. Curr Top Microbiol Immunol 2011; 344:269 - 78; http://dx.doi.org/10.1007/82_2010_114; PMID: 21086108
   PubMed Web of Science ®Google Scholar
• Speiser DE. A molecular profile of T-cell exhaustion in cancer. Oncoimmunology 2012; 1:369 - 71; http://dx.doi.org/10.4161/onci.18342; PMID: 22737618
   PubMed Web of Science ®Google Scholar
• Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, Hwu P, Radvanyi LG. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother 2011; 34:236 - 50; http://dx.doi.org/10.1097/CJI.0b013e318209e7ec; PMID: 21389874
   PubMed Web of Science ®Google Scholar
• Wang C, Wen T, Routy JP, Bernard NF, Sekaly RP, Watts TH. 4-1BBL induces TNF receptor-associated factor 1-dependent Bim modulation in human T cells and is a critical component in the costimulation-dependent rescue of functionally impaired HIV-specific CD8 T cells. J Immunol 2007; 179:8252 - 63; PMID: 18056369
   PubMed Web of Science ®Google Scholar